Cetuximab Every 2 Weeks Versus Standard Weekly Dosing Administration Schedule

References

• U.S. Food and Drug Administration . Erbitux Full Prescribing Information (2021). www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s277s280lbl.pdf (Accessed 12November2022).
   Google Scholar
• European Medicines Agency . Summary of product characteristics, Erbitux (2022). www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf (Accessed 12November2022).
   Google Scholar
• Japanese Pharmaceuticals and Medical Devices Agency . Package insert, Erbitux (2022).
   Google Scholar
• U.S. Food and Drug Administration . FDA approves new dosing regimen for cetuximab (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-new-dosing-regimen-cetuximab (Accessed 20November2022).
   Google Scholar
• Center for Drug Evaluation and Research . Approval package for Erbitux (2021). www.accessdata.fda.gov/drugsatfda_docs/nda/2021/125084Orig1s277,s280.pdf (Accessed: 20November2022).
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Colon Cancer V2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed (28 August 2023). To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Rectal Cancer V4.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed (28 August 2023). To view the most recent and complete version of the guideline go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
   Google Scholar
• New South Wales Cancer Institute . Colorectal metastatic cetuximab (two weekly) (2015). www.eviq.org.au/medical-oncology/colorectal/metastatic/1681-colorectal-metastatic-cetuximab-two-weekly (Accessed 12November2022).
   Google Scholar
• Vecchione L , StintzingS, PentheroudakisG, DouillardJY, LordickF. ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer. ESMO Open5(Suppl. 3), e000826 (2020).
   PubMedGoogle Scholar
• Kasper S , FochC, MessingerDet al. Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer. Eur. J. Cancer144, 291–301 (2021).
   PubMed Web of Science ®Google Scholar
• Lamy FX , BatechM, BoutmyEet al. Comparative effectiveness of weekly versus every-2-weeks cetuximab in metastatic colorectal cancer in a US-insured population. J. Comp. Eff. Res.9(16), 1117–1129 (2020).
   PubMed Web of Science ®Google Scholar
• Loft M , ShapiroJ, LeeMet al. Compliance with Therapeutic Goods Association prescribing information: weekly or second weekly cetuximab for the treatment of metastatic colorectal cancer. Intern. Med. J. doi:10.1111/imj.15835 (2022).
   PubMed Web of Science ®Google Scholar
• Cheng AL , CornelioG, ShenLet al. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase II APEC Study. Clin. Colorectal Cancer16(2), e73–e88 (2017).
   PubMed Web of Science ®Google Scholar
• Soda H , MaedaH, HasegawaJet al. Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. BMC Cancer15, 695 (2015).
   PubMed Web of Science ®Google Scholar
• Bossi P , KornekG, LanzettaGet al. Safety and feasibility of every-other-week maintenance cetuximab after first-line chemotherapy in patients with recurrent or metastatic head and neck squamous cell cancer. Head Neck35(10), 1471–1474 (2013).
   PubMed Web of Science ®Google Scholar
• Posch D , FuchsH, KornekGet al. Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer. Sci. Rep.6, 32946 (2016).
   PubMed Web of Science ®Google Scholar
• Hubbard JM , AlbertsSR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest. Cancer Res.6(2), 47–55 (2013).
   PubMedGoogle Scholar
• Lala M , LiTR, DeAlwis DPet al. A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation. Eur. J. Cancer131, 68–75 (2020).
   PubMed Web of Science ®Google Scholar
• Morrissey KM , MarchandM, PatelHet al. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting. Cancer Chemother. Pharmacol.84(6), 1257–1267 (2019).
   PubMed Web of Science ®Google Scholar
• Weiner LM , BelldegrunAS, CrawfordJet al. Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. Clin. Cancer Res.14(2), 502–508 (2008).
   PubMed Web of Science ®Google Scholar
• Yang BB , LumP, ChenAet al. Pharmacokinetic and pharmacodynamic perspectives on the clinical drug development of panitumumab. Clin. Pharmacokinet.49(11), 729–740 (2010).
   PubMed Web of Science ®Google Scholar
• Tabernero J , PfeifferP, CervantesA. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration?Oncologist13(2), 113–119 (2008).
   PubMed Web of Science ®Google Scholar
• Tabernero J , CiardielloF, RiveraFet al. Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study. Ann. Oncol.21(7), 1537–1545 (2010).
   PubMed Web of Science ®Google Scholar
• Tabernero J , CervantesA, RiveraFet al. Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study. J. Clin. Oncol.28(7), 1181–1189 (2010).
   PubMed Web of Science ®Google Scholar
• Brodowicz T , CiuleanuTE, RadosavljevicDet al. FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study. Ann. Oncol.24(7), 1769–1777 (2013).
   PubMed Web of Science ®Google Scholar
• Jensen BV , SchouJV, JohannesenHHet al. Cetuximab every second week with irinotecan in patients with metastatic colorectal cancer refractory to 5-FU, oxaliplatin, and irinotecan: KRAS mutation status and efficacy. J. Clin. Oncol.28(Suppl. 15), 3573–3573 (2010).
   Google Scholar
• Kotake M , AoyamaT, MunemotoYet al. Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). Oncol. Lett.13(2), 747–753 (2017).
   PubMed Web of Science ®Google Scholar
• Kasper S , MeilerJ, KnippHet al. Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial. Clin. Colorectal Cancer19 (4), 236–247; e236 (2020).
   PubMed Web of Science ®Google Scholar
• Fernandez-Plana J , PericayC, QuinteroGet al. Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). BMC Cancer14, 865 (2014).
   PubMed Web of Science ®Google Scholar
• Ji JH , ParkSH, LeeJet al. Prospective phase II study of neoadjuvant FOLFOX6 plus cetuximab in patients with colorectal cancer and unresectable liver-only metastasis. Cancer Chemother. Pharmacol.72(1), 223–230 (2013).
   PubMed Web of Science ®Google Scholar
• Personeni N , RimassaL, VerusioCet al. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. Clin. Colorectal Cancer14(3), 162–169 (2015).
   PubMed Web of Science ®Google Scholar
• Chayahara NEA . Phase II trial of bi-weekly cetuximab for recurrent or metastatic colorectal cancer (BIC-K trial). Ann. Oncol.27, vii77–vii78 (2016).
   Google Scholar
• Osumi H , ShinozakiE, MashimaTet al. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer. Cancer Sci.109(8), 2567–2575 (2018).
   PubMed Web of Science ®Google Scholar
• Kang MJ , HongYS, KimKPet al. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest. New Drugs30(4), 1607–1613 (2012).
   PubMed Web of Science ®Google Scholar
• Shitara K , YokotaT, TakahariDet al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for pre-treated metastatic colorectal cancer harboring wild-type KRAS. Jpn J. Clin. Oncol.40(7), 699–701 (2010).
   PubMed Web of Science ®Google Scholar
• Jensen BV , SchouJV, YilmazMet al. Cetuximab plus irinotecan administered biweekly with reduced infusion time to heavily pretreated patients with metastatic colorectal cancer and related RAS and BRAF mutation status. Int. J. Cancer doi:10.1002/ijc.33448 (2020). ( Online ahead of print).
   Web of Science ®Google Scholar
• Chen Y , CaoD, BiF, LiQ, QiuM. Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. Med. Oncol.31(5), 935 (2014).
   PubMed Web of Science ®Google Scholar
• Abdelwahab S , AzmyA, Abdel-AzizH, SalimH, MahmoudA. Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC). J. Cancer Res. Clin. Oncol.138(9), 1487–1492 (2012).
   PubMed Web of Science ®Google Scholar
• Folprecht G , HamannS, SchütteKet al. Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer. BMC Cancer14, 521 (2014).
   PubMed Web of Science ®Google Scholar
• Cremolini C , AntoniottiC, LonardiSet al. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase II Clinical Trial. JAMA Oncol.4(4), 529–536 (2018).
   PubMed Web of Science ®Google Scholar
• Tveit KM , GurenT, GlimeliusBet al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol.30(15), 1755–1762 (2012).
   PubMed Web of Science ®Google Scholar
• Pfeiffer P , SorbyeH, QvortrupCet al. Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation Group. Clin. Colorectal Cancer14(3), 170–176 (2015).
   PubMed Web of Science ®Google Scholar
• Shitara K , YukiS, YoshidaMet al. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines. Invest. New Drugs30(2), 787–793 (2012).
   PubMed Web of Science ®Google Scholar
• Ychou M , RivoireM, ThezenasSet al. Chemotherapy (doublet or triplet) plus targeted therapy by RAS status as conversion therapy in colorectal cancer patients with initially unresectable liver-only metastases. The UNICANCER PRODIGE-14 randomised clinical trial. Br. J. Cancer126(9), 1264–1270 (2022).
   PubMed Web of Science ®Google Scholar
• Guren TK , ThomsenM, KureEHet al. Cetuximab in treatment of metastatic colorectal cancer: final survival analyses and extended RAS data from the NORDIC-VII study. Br. J. Cancer116(10), 1271–1278 (2017).
   PubMed Web of Science ®Google Scholar
• Sobrero AF , MaurelJ, FehrenbacherLet al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J. Clin. Oncol.26(14), 2311–2319 (2008).
   PubMed Web of Science ®Google Scholar
• Carneiro BA , RamanathanRK, FakihMGet al. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer. Clin. Colorectal Cancer11(1), 53–59 (2012).
   PubMed Web of Science ®Google Scholar
• Pfeiffer P , NielsenD, BjerregaardJet al. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann. Oncol.19(6), 1141–1145 (2008).
   PubMed Web of Science ®Google Scholar
• Martín-Martorell P , RosellóS, Rodríguez-BraunEet al. Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. Br. J. Cancer99(3), 455–458 (2008).
   PubMed Web of Science ®Google Scholar
• Mrabti H , DeLa Fouchardiere C, DesseigneFet al. Irinotecan associated with cetuximab given every 2 weeks versus cetuximab weekly in metastatic colorectal cancer. J. Cancer Res. Ther.5(4), 272–276 (2009).
   PubMed Web of Science ®Google Scholar
• Bouchahda M , MacarullaT, LiedoGet al. Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysis. Med. Oncol.28(Suppl. 1), S253–S258 (2011).
   PubMedGoogle Scholar
• Roca JM , AlonsoV, PericayCet al. Cetuximab given every 2 weeks plus irinotecan is an active and safe option for previously treated patients with metastatic colorectal cancer. Chemotherapy56(2), 142–146 (2010).
   PubMed Web of Science ®Google Scholar
• Bokemeyer C , BondarenkoI, HartmannJTet al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann. Oncol.22(7), 1535–1546 (2011).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , LenzHJ, KöhneCHet al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J. Clin. Oncol.33(7), 692–700 (2015).
   PubMed Web of Science ®Google Scholar
• Cunningham D , HumbletY, SienaSet al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351(4), 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Fiore FD , CutsemEV, Laurent-PuigPet al. Role of KRAS mutation in predicting response, progression-free survival, and overall survival in irinotecan-refractory patients treated with cetuximab plus irinotecan for a metastatic colorectal cancer: analysis of 281 individual data from published series. J. Clin. Oncol.26(Suppl. 15), 4035 (2008).
   PubMedGoogle Scholar
• Wilke H , Glynne-JonesR, ThalerJet al. Cetuximab Plus Irinotecan in Heavily Pretreated Metastatic Colorectal Cancer Progressing on Irinotecan: MABEL Study. J. Clin. Oncol.26(33), 5335–5343 (2008).
   PubMed Web of Science ®Google Scholar
• Lim R , SunY, ImSAet al. Cetuximab plus irinotecan in pretreated metastatic colorectal cancer patients: the ELSIE study. World J. Gastroenterol.17(14), 1879–1888 (2011).
   PubMed Web of Science ®Google Scholar
• Buzaid AC , MathiasCde C, PerazzoFet al. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study. Clin. Colorectal Cancer9(5), 282–289 (2010).
   PubMed Web of Science ®Google Scholar
• Van Cutsem E , KöhneCH, LángIet al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J. Clin. Oncol.29(15), 2011–2019 (2011).
   PubMed Web of Science ®Google Scholar
• Parikh AR , Gonzalez-GugelE, SmolyakovaNet al. Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis. The Oncologist27(5), 371–379 (2022).
   PubMed Web of Science ®Google Scholar
• Rouyer M , FrançoisE, CunhaASet al. Effectiveness of Cetuximab as First-Line Therapy for Patients With Wild-Type KRAS and Unresectable Metastatic Colorectal Cancer in Real-Life Practice: Results of the EREBUS Cohort. Clin. Colorectal Cancer17(2), 129–139 (2018).
   PubMed Web of Science ®Google Scholar
• Sahm S , GoehlerT, Hering-SchubertCet al. Outcome of patients with KRAS exon 2 wildtype (KRAS-wt) metastatic colorectal carcinoma (mCRC) with cetuximab-based first-line treatment in the noninterventional study ERBITAG and impact of comorbidity and age. J. Clin. Oncol.34(Suppl. 4), 651 (2016).
   Google Scholar
• Kasper S , ChengAL, RouyerMet al. Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left and right-sided primary tumor location. Presented at: ESMO World Congress on Gastrointestinal Cancer.30 June–3 July 2021.
   Google Scholar
• Kasper S , FochC, EsserRet al. Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location. Eur. J. Cancer180, 85–88 (2023).
   PubMed Web of Science ®Google Scholar
• Kasper S , ChengAL, RouyerMet al. Comparison of cetuximab every-2-weeks versus standard once-weekly administration for the first-line treatment of RAS wild-type metastatic colorectal cancer among patients with left- and right-sided primary tumor location. Presented at: ESMO.16–21 September 2021.
   Google Scholar
• Pescott CP , BoutmyE, BatechM, RongaP, LamyFX. Real-world healthcare resource utilization and costs of weekly versus every-2-week cetuximab in metastatic colorectal cancer. J. Comp. Eff. Res.10(5), 353–364 (2021).
   PubMed Web of Science ®Google Scholar
• Guigay J , FayetteJ, DilliesAFet al. Cetuximab, docetaxel, and cisplatin as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: a multicenter, phase II GORTEC study. Ann. Oncol.26(9), 1941–1947 (2015).
   PubMed Web of Science ®Google Scholar
• Fury MG , ShermanE, LisaDet al. A randomized Phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer. J. Natl Compr. Cancer Netw.10(11), 1391–1398 (2012).
   PubMed Web of Science ®Google Scholar
• Guigay J , ChamoreyE, LefebvreGet al. Observational, prospective, Phase IV study in patients with first-line recurrent and/or metastatic squamous cell carcinoma of the head and neck treated with cetuximab and platinum-based therapy: DIRECT. Cancer Rep. (Hoboken)5(2), e1467 (2021).
   PubMedGoogle Scholar
• Klinghammer K , GaulerT, DietzAet al. Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108). Eur. J. Cancer122, 53–60 (2019).
   PubMed Web of Science ®Google Scholar
• Guigay J , AupérinA, FayetteJet al. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, Phase II trial. Lancet Oncol.22(4), 463–475 (2021).
   PubMed Web of Science ®Google Scholar